[go: up one dir, main page]

WO2012011118A3 - Development of a fixed dose combination dosage form containing ramipril and carvedilol - Google Patents

Development of a fixed dose combination dosage form containing ramipril and carvedilol Download PDF

Info

Publication number
WO2012011118A3
WO2012011118A3 PCT/IN2011/000335 IN2011000335W WO2012011118A3 WO 2012011118 A3 WO2012011118 A3 WO 2012011118A3 IN 2011000335 W IN2011000335 W IN 2011000335W WO 2012011118 A3 WO2012011118 A3 WO 2012011118A3
Authority
WO
WIPO (PCT)
Prior art keywords
carvedilol
dosage form
development
fixed dose
form containing
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Ceased
Application number
PCT/IN2011/000335
Other languages
French (fr)
Other versions
WO2012011118A2 (en
Inventor
Purshotama Sagi Reddy Babu Reddy
R. Venkata Emani
Ravichandran Mahalingam
Ravi Jayapal
Bhaskara Jasti Rao
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Individual
Original Assignee
Individual
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Individual filed Critical Individual
Publication of WO2012011118A2 publication Critical patent/WO2012011118A2/en
Anticipated expiration legal-status Critical
Publication of WO2012011118A3 publication Critical patent/WO2012011118A3/en
Ceased legal-status Critical Current

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/40—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil
    • A61K31/403—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil condensed with carbocyclic rings, e.g. carbazole
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/13—Amines
    • A61K31/135—Amines having aromatic rings, e.g. ketamine, nortriptyline
    • A61K31/138—Aryloxyalkylamines, e.g. propranolol, tamoxifen, phenoxybenzamine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/55—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having seven-membered rings, e.g. azelastine, pentylenetetrazole
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A61K9/2072—Pills, tablets, discs, rods characterised by shape, structure or size; Tablets with holes, special break lines or identification marks; Partially coated tablets; Disintegrating flat shaped forms
    • A61K9/2077—Tablets comprising drug-containing microparticles in a substantial amount of supporting matrix; Multiparticulate tablets
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A61K9/2072—Pills, tablets, discs, rods characterised by shape, structure or size; Tablets with holes, special break lines or identification marks; Partially coated tablets; Disintegrating flat shaped forms
    • A61K9/2086—Layered tablets, e.g. bilayer tablets; Tablets of the type inert core-active coat
    • A61K9/209—Layered tablets, e.g. bilayer tablets; Tablets of the type inert core-active coat containing drug in at least two layers or in the core and in at least one outer layer

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Epidemiology (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicinal Preparation (AREA)

Abstract

A pharmaceutical preparation for oral administration comprising a combination of an ACE inhibitor such as Ramipril, benzapril or a pharmaceutically acceptable salt thereof, and a non selective Beta-blocker such as Carvedilol, propranolol etc, or a pharmaceutically acceptable salt thereof, wherein the ACE inhibitor compound is in immediate release form, the beta-blocker compound is in immediate release form and, the combination is in a solid fixed-unit dosage form such as a capsule or a tablet.
PCT/IN2011/000335 2010-05-13 2011-05-13 Development of a fixed dose combination dosage form containing ramipril and carvedilol Ceased WO2012011118A2 (en)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US39557710P 2010-05-13 2010-05-13
US61/395,577 2010-05-13

Publications (2)

Publication Number Publication Date
WO2012011118A2 WO2012011118A2 (en) 2012-01-26
WO2012011118A3 true WO2012011118A3 (en) 2020-11-26

Family

ID=45497233

Family Applications (1)

Application Number Title Priority Date Filing Date
PCT/IN2011/000335 Ceased WO2012011118A2 (en) 2010-05-13 2011-05-13 Development of a fixed dose combination dosage form containing ramipril and carvedilol

Country Status (1)

Country Link
WO (1) WO2012011118A2 (en)

Families Citing this family (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN107970255A (en) * 2017-12-14 2018-05-01 青岛农业大学 Treat the pharmaceutical composition and its tablet and preparation method of congestive heart failure

Citations (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US20050032879A1 (en) * 2003-08-07 2005-02-10 Temple Okarter Formulations and use of a beta-blocker and an ACE-inhibitor for the treatment of cardiovascular diseases
WO2007010501A2 (en) * 2005-07-22 2007-01-25 Ranbaxy Laboratories Limited A pharmaceutical composition comprising a combination of beta blocker and an ace inhibitor
US20090215852A1 (en) * 2005-03-21 2009-08-27 Chroma Group, Inc. Compositions and methods for ameliorating cachexia
US20150094345A1 (en) * 2012-02-17 2015-04-02 Egis Gyogyszergyar Zrt. Pharmaceutical formulation having improved stability

Patent Citations (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US20050032879A1 (en) * 2003-08-07 2005-02-10 Temple Okarter Formulations and use of a beta-blocker and an ACE-inhibitor for the treatment of cardiovascular diseases
US20090215852A1 (en) * 2005-03-21 2009-08-27 Chroma Group, Inc. Compositions and methods for ameliorating cachexia
WO2007010501A2 (en) * 2005-07-22 2007-01-25 Ranbaxy Laboratories Limited A pharmaceutical composition comprising a combination of beta blocker and an ace inhibitor
US20150094345A1 (en) * 2012-02-17 2015-04-02 Egis Gyogyszergyar Zrt. Pharmaceutical formulation having improved stability

Also Published As

Publication number Publication date
WO2012011118A2 (en) 2012-01-26

Similar Documents

Publication Publication Date Title
MX377251B (en) CONTROLLED-RELEASE DOSAGE FORMS FOR HIGH-DOSE, WATER-SOLUBLE, HYGROSCOPIC DRUG SUBSTANCES.
MX2020009329A (en) Pharmaceutical formulations containing dapagliflozin propylene glycol hydrate.
MY157307A (en) Pharmaceutical formulation in the form of bilayered tablets comprising hmg-coa reductase inhibitor and irbersartan
PH12014501408A1 (en) Immediate release multi unit pellet system
NZ601595A (en) Oral formulations and lipophilic salts of methylnaltrexone
WO2011012322A3 (en) Synthesis and use of vildagliptin for the preparation of pharmaceutical dosage forms
WO2012010669A3 (en) Medicinal drug for oral administration comprising a mixture of silodosin and a basic copolymer
CR20110704A (en) COMPOSITIONS OF FIXED DOSAGE SOLID PHARMACEUTICALS THAT INCLUDE IRBESARTAN AND AMYLODIPINE, ITS PREPARATION AND THERAPEUTIC APPLICATION
WO2014114255A3 (en) Positioning, quick-release bioadhesion agent and use
NZ594311A (en) Pharmaceutical composition comprising tamsulosin and solifenacin for oral administration
PH12015500823A1 (en) Modified release formulations for oprozomib
PH12015500395A1 (en) Pharmaceutical composite capsule formulation comprising irbesartan and hmg-coa reductase inhibitor
TR201001417A1 (en) Cefdinir formulation with improved dissolution rate
UA105285C2 (en) Solid pharmaceutical composition comprising ramipril and amlodipine besilate and method for its preparation
WO2012011118A3 (en) Development of a fixed dose combination dosage form containing ramipril and carvedilol
IN2014CN02343A (en) Oral formulations containing hyaluronic acid for sustained drug release
WO2011108882A3 (en) Pharmaceutical composition for the prevention or treatment of osteoarthritis containing rebamipide as an active ingredient
WO2012068076A3 (en) Pharmaceutical formulations containing soluble drugs
WO2011095801A3 (en) Liquid pharmaceutical composition for buccal administration comprising morphine
WO2013057569A3 (en) Extended release pharmaceutical composition containing amoxicillin and clavulanic acid
MX2009006735A (en) Gelatin capsules comprising an acid.
WO2013054178A8 (en) Extended release pharmaceutical compositions containing carmabazepine
WO2012080984A3 (en) Controlled-release pharmaceutical tablet for oral administration
TH127122A (en) Alis Kyren and Amlodinine Recipes
TR201102142A1 (en) PHARMACEUTICAL COMPOSITION CONTAINING ENTECAVIRE OR PHARMACEUTICAL ACCEPTABLE SALTS

Legal Events

Date Code Title Description
121 Ep: the epo has been informed by wipo that ep was designated in this application

Ref document number: 11809377

Country of ref document: EP

Kind code of ref document: A2

NENP Non-entry into the national phase

Ref country code: DE

122 Ep: pct application non-entry in european phase

Ref document number: 11809377

Country of ref document: EP

Kind code of ref document: A2